This study aims to look at patient and physician satisfaction of long term Glabellar lines (GL) treatment with Dysport in a real life setting. It will also allow better understanding of what patients expect from the treatment, and the injection practices used by doctors.

Inclusion Criteria:

• Adult patient with moderate to severe GL naïve of any type of aesthetic treatment/procedure (invasive and non-invasive) for GL who provided written informed consent to take part.
• Patient who has prior to and independent of the study decided to undergo long term treatment of GL only (at least three cycles).
• Patient able to comply with the protocol (completion of web questionnaires).
• Patient whom physician intended to treat with Dysport independent of participation in the study.

Exclusion Criteria:

• Patient already included in this study.
• Participation in an interventional trial within 30 days prior to study entry.
• Patient who is at risk in terms of precautions, warnings, and contraindication (follow local Summary of Product Characteristics (SmPC) of Dysport).
• Female patient who is pregnant, nursing or planning a pregnancy during the study.
• Hypersensitivity to Dysport® or to its excipients.
• Presence of infection at the proposed injection sites.
• Presence of myasthenia gravis, Eaton Lambert syndrome or amyotrophic lateral sclerosis.

Private practices and clinics